GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Quick Ratio

Allarity Therapeutics (Allarity Therapeutics) Quick Ratio : 0.13 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Allarity Therapeutics's quick ratio for the quarter that ended in Mar. 2024 was 0.13.

Allarity Therapeutics has a quick ratio of 0.13. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Allarity Therapeutics's Quick Ratio or its related term are showing as below:

ALLR' s Quick Ratio Range Over the Past 10 Years
Min: 0.13   Med: 0.44   Max: 1.99
Current: 0.13

During the past 5 years, Allarity Therapeutics's highest Quick Ratio was 1.99. The lowest was 0.13. And the median was 0.44.

ALLR's Quick Ratio is ranked worse than
95.28% of 1547 companies
in the Biotechnology industry
Industry Median: 3.59 vs ALLR: 0.13

Allarity Therapeutics Quick Ratio Historical Data

The historical data trend for Allarity Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Quick Ratio Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
0.71 0.31 1.03 0.44 0.14

Allarity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.29 0.28 0.14 0.13

Competitive Comparison of Allarity Therapeutics's Quick Ratio

For the Biotechnology subindustry, Allarity Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allarity Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Quick Ratio falls into.



Allarity Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Allarity Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.971-0)/14.167
=0.14

Allarity Therapeutics's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2.295-0)/18.008
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allarity Therapeutics  (NAS:ALLR) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Allarity Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Allarity Therapeutics (Allarity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
24 School Street, 2nd Floor, Boston, MA, USA
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Executives
Laura Benjamin director 168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano director 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown officer: Chief Financial Officer C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi director, officer: Chief Executive Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen officer: Chief Scientific Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen officer: Chief Financial Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore director C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen officer: SVP, Information Technology 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem officer: SVP, Chief Business Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh officer: Chief Medical Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps 10 percent owner VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass 10 percent owner JERNBAEK ALLE 5, HELSINGE G7 DK-3200

Allarity Therapeutics (Allarity Therapeutics) Headlines